John Libbey Eurotext

Hépato-Gastro & Oncologie Digestive

MENU

Sofosbuvir and NS5A inhibitors in HIV/HCV co-infected patients Volume 23, supplement 1, Février 2016

Author
Hôpital Cochin,
département d’hépatologie,
unité d’hépatologie,
27 rue du Faubourg Saint Jacques,
75014 Paris,
France ;
Université Paris Descartes ;
Inserm U-818 et UMS20,
Institut Pasteur,
Paris,
France
* Tirés à part

Human Immune Deficiency (HIV) virus increases the progression of liver fibrosis in Hepatitis C virus (HCV)-infected patients living with HIV (PLWHIV) but also, as in the non HIV-infected population, the risks of extra-hépatic morbidity and mortality. This explains that HCV infection is still associated, despite the progress of immune restoration and the reduction of the hepatotoxicity of antiretrovirals, with a significant risk of total, hepatic and extra-hepatic mortality. The sustained virologic response (SVR) corresponding to virologic recovery significantly reduces the overall mortality. Such a recovery has to be offered to all co-infected PLWHIV (like theorically to all HCV-infected patients) and this is possible in France today where co-infected PLWHIV should be the first population in whom HCV elimination appears to be likely in the next future. This review summarizes most of recent results which have been obtained with the combination of Sofosbuvir and a NS5A inhibitor : it appears to be one of the optimal therapeutic options in PLWHIV since achieving more than 90% of SVR, similar to that in non-HIV infected patients.